Mar 27, 2020
Luye Pharma Continues to Deliver Strong Growth in 2019
Feb 10, 2020
Luye Pharma Grants Cipla Medpro Exclusive Distribution and Marketing Rights for Seroquel® and Seroquel XR® in South Africa and Certain Neighbouring Countries
Nov 04, 2019
Luye Pharma's LY03004 Manufacturing Facility Successfully Passes U.S. FDA Pre-approval Inspection with Zero Observation
Sep 03, 2019
The First Asia Pacific Psychiatry Symposium Takes Place
Aug 29, 2019
Luye Pharma First Half of 2019 Results: Strong Revenue Growth and Substantial Development of R&D Product Pipelines
May 30, 2019
Luye Pharma's Rykindo® NDA Filing Accepted by the U.S. FDA
Jan 16, 2019
Luye Pharma Reaches Strategic Partnership with AstraZeneca, Strengthens Commitment to Cardiovascular Therapeutic Field
Sep 07, 2018
Luye Pharma's Goserelin Acetate Extended-release Microspheres Start Phase III Clinical Trials in China, Paralleling Smooth Progress with U.S. Regulators
Aug 29, 2018
Luye Pharma Releases its Financial Results for the First Half of 2018: Double-Digit Growth in Core Product Sales, Exceeded Expectations in Sales, R&D and M&As
Jul 22, 2018
Luye Pharma Well Positioned for CNS Market with the Approval of A New Indication for Seroquel XR in China
Jun 07, 2018
Luye expanding I-O deal with U.S. firm Elpis to focus on CAR T therapies
May 27, 2018
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
Mar 29, 2018
Luye Pharma: A Healthy Thirty Percent Annual Growth Rate, with Competitive Product Pipelines across Different Therapeutic Areas